A comprehensive analysis of clinical and polygenic germline influences on somatic mutational burden

Am J Hum Genet. 2024 Feb 1;111(2):242-258. doi: 10.1016/j.ajhg.2023.12.010. Epub 2024 Jan 10.

Abstract

Tumor mutational burden (TMB), the total number of somatic mutations in the tumor, and copy number burden (CNB), the corresponding measure of aneuploidy, are established fundamental somatic features and emerging biomarkers for immunotherapy. However, the genetic and non-genetic influences on TMB/CNB and, critically, the manner by which they influence patient outcomes remain poorly understood. Here, we present a large germline-somatic study of TMB/CNB with >23,000 individuals across 17 cancer types, of which 12,000 also have extensive clinical, treatment, and overall survival (OS) measurements available. We report dozens of clinical associations with TMB/CNB, observing older age and male sex to have a strong effect on TMB and weaker impact on CNB. We additionally identified significant germline influences on TMB/CNB, including fine-scale European ancestry and germline polygenic risk scores (PRSs) for smoking, tanning, white blood cell counts, and educational attainment. We quantify the causal effect of exposures on somatic mutational processes using Mendelian randomization. Many of the identified features associated with TMB/CNB were additionally associated with OS for individuals treated at a single tertiary cancer center. For individuals receiving immunotherapy, we observed a complex relationship between PRSs for educational attainment, self-reported college attainment, TMB, and survival, suggesting that the influence of this biomarker may be substantially modified by socioeconomic status. While the accumulation of somatic alterations is a stochastic process, our work demonstrates that it can be shaped by host characteristics including germline genetics.

Keywords: cancer; copy number burden; fine-scale ancestry; overall survival; polygenic risk scores; somatic burden; tumor mutational burden.

MeSH terms

  • Biomarkers, Tumor / genetics
  • Germ Cells / pathology
  • Humans
  • Immunotherapy
  • Male
  • Mutation / genetics
  • Neoplasms* / genetics
  • Neoplasms* / pathology

Substances

  • Biomarkers, Tumor